-
Low-Molecular Weight Inhibitors of the Alternative Pathway
2026-09-18
Schubart and colleagues review how selective low-molecular-weight inhibitors of complement factor B and factor D can interrupt alternative-pathway amplification in complement-mediated disease. The analysis connects pathway biochemistry with cellular assays, animal models, and clinical translation, providing a framework for interpreting compounds such as LNP023 in complement activation research.
-
KPT-330 (Selinexor) | CRM1 Assay Guide
2026-09-18
This scenario-driven guide explains how KPT-330 (Selinexor), selective CRM1 inhibitor (SKU B1464), can support reproducible viability, proliferation, apoptosis, and nuclear-export experiments. It covers stock preparation, concentration selection, orthogonal data interpretation, cross-domain osteoclast studies, and practical vendor-selection criteria.
-
Puerarin Activates NO Signaling in Dental Follicle Cells
2026-09-17
The reference study shows that puerarin enhances osteogenic differentiation of rat dental follicle cells while increasing nitric oxide, cGMP, osteogenic markers, and components of the SGC–PKG signaling axis. Pharmacological inhibition with L-NMMA reversed these effects, supporting a functional role for nitric oxide pathway activation in periodontal regeneration research.
-
Palonosetron for Chemotherapy-Induced Nausea and Vomiting
2026-09-17
The review by Ruhlmann and Herrstedt examines how palonosetron differs pharmacologically from earlier 5-HT3 receptor antagonists and whether those differences improve prevention of chemotherapy-induced nausea and vomiting. Its main practical contribution is to connect long receptor residence, high affinity, allosteric binding, and positive cooperativity with clinical evidence across acute and delayed emesis, while emphasizing that combination therapy remains important.
-
A23187, Free Acid for Calcium Signaling Assays
2026-09-16
A23187, free acid is a versatile calcium ionophore for connecting intracellular Ca2+ elevation with signaling, mitochondrial apoptosis, ROS generation, and functional tissue responses. This workflow-focused guide shows how to separate acute calcium effects from delayed cell killing and improve assay reproducibility.
-
LPS Protection of Macrophages: System Xc− and ABCC1
2026-09-15
Qiao and colleagues show that lipopolysaccharide protects macrophages from antitumor drug-induced injury through a pathway involving system Xc−, glutathione synthesis, and ABCC1-associated drug handling. The study distinguishes this macrophage-protective response from tumor-cell protection and provides a useful framework for interpreting pharmacological inhibition of oxidative-stress and transporter pathways.
-
TaqI Restriction Endonuclease Workflow Guide
2026-09-15
TaqI Restriction Endonuclease enables rapid, sequence-specific cleavage of plasmid DNA, PCR products, and genomic DNA when sticky-end generation is needed. This guide covers setup, gel-based checking, and troubleshooting while limiting use to scientific research rather than diagnostic, clinical, or medical applications.
-
EZ Cap™ Cy5 EGFP mRNA (5-moUTP) Workflows
2026-09-14
Separate nanoparticle uptake from productive translation with a single dual-fluorescence reporter. This practical guide shows how to use Cy5 tracking and EGFP expression to validate delivery systems, tune transfection conditions, and troubleshoot immune or viability artifacts.
-
LPS Protection of Macrophages via System Xc−
2026-09-14
A 2026 study reports that lipopolysaccharide selectively protects macrophages from antitumor drug injury without providing comparable protection to tumor cells. Its experiments connect this phenotype to system Xc−, glutathione preservation, and ABCC1-associated drug handling, offering a useful framework for studying immune-cell resistance during chemotherapy.
-
TH287 MTH1 Inhibitor for Radiosensitization
2026-09-13
TH287 turns oxidized nucleotide stress into a practical cancer-cell radiosensitization workflow. A 12-hour drug-to-irradiation interval, paired with apoptosis and cell-cycle readouts, provides a focused framework for studying CRPC models and DNA damage responses.
-
TRIM21, ERK1/2, and Drug Resistance in Pituitary Adenomas
2026-09-12
The reference study identifies TRIM21 as a context-dependent regulator of pituitary adenoma growth and dopamine-agonist resistance through K27-linked ubiquitination and phosphorylation control of ERK1/2. Its combination of CRISPR screening, biochemical validation, animal studies, and NanoBiT drug screening provides a framework for connecting post-translational signaling to therapeutic response.
-
Tubastatin A for Reliable Cell Assays
2026-09-12
Learn how Tubastatin A (SKU A4101) can improve the interpretation of viability, proliferation, and cytotoxicity experiments through selective HDAC6 inhibition, controlled DMSO formulation, and orthogonal pathway readouts. The article connects practical assay design with recent porcine cardiac-injury evidence while clearly distinguishing biochemical potency from cell-based dose response.
-
MK-571 (L-660,711) Assay Guide
2026-09-11
This scenario-based guide explains how MK-571 (L-660,711) and SKU B7023 can improve experimental control in leukotriene, macrophage, viability, and multidrug-resistance assays. It covers mechanism, DMSO handling, orthogonal endpoint validation, and practical vendor-selection criteria.
-
MK-571: A Dual-Readout Strategy for Inflammation
2026-09-11
MK-571, also known as L-660,711, combines potent cysLT1 receptor antagonism with MRP1-associated transporter activity. This guide develops a dual-readout framework for leukotriene-mediated inflammation research and macrophage drug-resistance assays, helping researchers avoid misleading single-mechanism interpretations.
-
(S)-(+)-Ibuprofen: COX Inhibitor Workflows
2026-09-10
Build more interpretable inflammation assays with the pharmacologically active ibuprofen enantiomer, from enzyme-level COX profiling to cell-based prostaglandin measurements. This guide combines practical dosing, solvent controls, translational design, and troubleshooting for reproducible COX inhibitor research.